Opinion|Videos|November 25, 2024
Operationalizing Bispecific Therapy and the Impact of CAR T Advancements on Sequencing
Key Takeaways
- Strategic sequencing of bispecific antibodies and CAR T-cell therapy is crucial for optimizing outcomes in RRMM treatment.
- Operational challenges include coordinating multidisciplinary teams, managing toxicities, and ensuring timely access to therapies.
Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has this impacted sequencing of bispecific antibodies and CAR T-cell therapy for patients at your institution?
- What operational challenges do institutions often face in terms of the use of bispecific antibodies in patients with RRMM, and how has your institution addressed these challenges?
Advertisement
Related to this article
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5